FDA clears Tria Beauty's Age-Defying Laser

DUBLIN, Calif. — Tria Beauty, a maker of light-based skin care, has received clearance from the Food and Drug Administration for the company's Age-Defying Laser, the company has announced.

Utilizing a proprietary version of the same non-ablative fractional laser technology used by dermatologists and plastic surgeons in-office, the Age-Defying Laser is designed to treat multiple signs of facial aging.  This product expands the Tria portfolio into the anti-aging category and furthers Tria's mission of providing consumers with advanced skin care solutions previously only available in-office — and at a fraction of the cost and with the convenience of home use.

"The Age-Defying Laser represents a major breakthrough that allows consumers to safely and effectively use professional technology to get dramatic anti-aging results at home," said Nicole Landberg, VP, GM of Americas & Europe. "According to the American Society of Plastic Surgeons, in-office fractional laser therapy has skyrocketed in the last decade and now is widely accepted as the gold standard for treating fine lines, wrinkles and discoloration with minimal downtime. We are pleased to make this effective, safe and innovative technology available to a much broader group of women."

Used in a simple regimen of short daily treatments, the Age-Defying Laser is designed to deliver anti-aging results. In a series of clinical studies, independent dermatologists evaluated skin characteristics before and after use of the Age-Defying Laser and observed significant improvement in wrinkles and uneven texture, according to the company. In addition, 76% of users reported reductiona in fine lines and wrinkles, and 95% of users noticed smoother skin and an improvement in overall appearance. Users reported visible results in as few as two weeks, with optimal results occurring for most users in eight weeks.

The Age-Defying Laser will be available on TriaBeauty.com and select retailers in early 2014.


Login or Register to post a comment.